CASADEI GARDINI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.798
AS - Asia 4.834
EU - Europa 4.418
SA - Sud America 810
AF - Africa 130
OC - Oceania 35
Continente sconosciuto - Info sul continente non disponibili 4
Totale 24.029
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.646
GB - Regno Unito 1.766
SG - Singapore 1.563
CN - Cina 985
VN - Vietnam 682
HK - Hong Kong 642
BR - Brasile 629
IT - Italia 484
SE - Svezia 436
FI - Finlandia 402
DE - Germania 382
FR - Francia 238
RU - Federazione Russa 207
TR - Turchia 184
ID - Indonesia 164
IN - India 118
BG - Bulgaria 107
KR - Corea 84
IE - Irlanda 80
CA - Canada 67
AR - Argentina 58
JP - Giappone 56
BD - Bangladesh 54
IQ - Iraq 48
NL - Olanda 45
AE - Emirati Arabi Uniti 34
MX - Messico 33
ZA - Sudafrica 33
BE - Belgio 32
PK - Pakistan 32
UA - Ucraina 32
AT - Austria 31
CH - Svizzera 26
TH - Thailandia 25
CL - Cile 24
EC - Ecuador 24
SA - Arabia Saudita 23
VE - Venezuela 22
PH - Filippine 21
EG - Egitto 20
ES - Italia 20
RO - Romania 20
NZ - Nuova Zelanda 19
CO - Colombia 17
AU - Australia 15
MA - Marocco 15
PL - Polonia 15
PE - Perù 14
JO - Giordania 13
PT - Portogallo 13
CZ - Repubblica Ceca 12
KE - Kenya 12
MY - Malesia 12
LT - Lituania 11
PY - Paraguay 11
UZ - Uzbekistan 11
BZ - Belize 9
CR - Costa Rica 9
DZ - Algeria 9
JM - Giamaica 9
NP - Nepal 9
TN - Tunisia 9
DK - Danimarca 8
IL - Israele 8
IR - Iran 8
NO - Norvegia 8
AZ - Azerbaigian 7
SK - Slovacchia (Repubblica Slovacca) 7
TW - Taiwan 7
BO - Bolivia 6
OM - Oman 6
PS - Palestinian Territory 6
BY - Bielorussia 5
DO - Repubblica Dominicana 5
KZ - Kazakistan 5
SN - Senegal 5
UY - Uruguay 5
BH - Bahrain 4
ET - Etiopia 4
GA - Gabon 4
GT - Guatemala 4
HU - Ungheria 4
LU - Lussemburgo 4
RS - Serbia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
CI - Costa d'Avorio 3
GR - Grecia 3
HN - Honduras 3
LK - Sri Lanka 3
NG - Nigeria 3
PA - Panama 3
AO - Angola 2
BB - Barbados 2
GE - Georgia 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
LB - Libano 2
LV - Lettonia 2
Totale 23.987
Salva come PNG Salva come JPEG
Città #
Fairfield 2.212
Ashburn 1.448
Santa Clara 1.332
Southend 1.304
Singapore 1.066
Woodbridge 907
Seattle 874
Houston 781
Cambridge 732
Chandler 692
Wilmington 683
Hong Kong 629
Helsinki 379
Dearborn 324
Nyköping 307
Ann Arbor 300
London 300
San Jose 298
Council Bluffs 210
Beijing 200
Ho Chi Minh City 163
San Diego 161
Izmir 157
Dong Ket 155
Hanoi 147
Jakarta 147
The Dalles 142
New York 113
Lauterbourg 110
Sofia 106
Princeton 103
Los Angeles 97
Eugene 93
Phoenix 91
Hefei 80
Dublin 77
Shanghai 74
Chicago 68
São Paulo 68
Modena 63
Milan 55
Munich 55
Bremen 47
Orem 46
Seoul 46
Tokyo 46
Buffalo 42
Redondo Beach 36
Dallas 33
Frankfurt am Main 31
Redwood City 28
Boardman 27
Bupyeong-gu 27
Da Nang 24
Atlanta 22
Brussels 21
Mumbai 21
Nuremberg 21
Salt Lake City 21
Chennai 20
Norwalk 20
Amsterdam 19
Auckland 19
Guangzhou 18
Montreal 18
Rio de Janeiro 18
San Mateo 18
Baghdad 17
Bologna 17
Johannesburg 17
Moscow 17
Paris 17
Zhengzhou 17
Belo Horizonte 16
Haiphong 16
Kunming 16
Turku 16
Brasília 15
Vienna 15
Falkenstein 14
Genoa 14
Quito 14
Stockholm 14
Toronto 14
Zurich 14
Portsmouth 13
Rome 13
Amman 12
Curitiba 12
Denver 12
San Francisco 12
Santiago 12
Düsseldorf 11
Falls Church 11
Lima 11
Mexico City 11
Nanjing 11
Salvador 11
Campinas 10
Hounslow 10
Totale 18.444
Salva come PNG Salva come JPEG
Nome #
Chemotherapy and palliative care near end-of life: Examining the appropriateness at a cancer institute for colorectal cancer patients 603
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: Indicators of suspected adverse reactions 495
Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial 414
Metabolic disorders across hepatocellular carcinoma in Italy 327
Immunotherapy for colorectal cancer: where are we heading? 322
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 309
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 307
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 298
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 296
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 281
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma 275
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 274
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma 274
1H-NMR based serum metabolomics highlights different specific biomarkers between early and advanced hepatocellular carcinoma stages 274
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients 273
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 272
Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy 272
Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life 271
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 271
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 270
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 269
Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours 264
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 263
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 262
Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: A case report and results from a cytoflourimetric assay of platelet fibrinogen receptor 257
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 256
Immunotherapeutic approaches for hepatocellular carcinoma 253
Efficacy of sorafenib in BRAF-mutated nonsmall- cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma: A case report 252
Complete Response in Patient with Metastatic Breast Cancer Treated with Metronomic Chemotherapy 252
Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study 251
Prolonged pemetrexed infusion plus gemcitabine in refractory metastatic colorectal cancer: Preclinical rationale and phase II study results 251
Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study 250
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial 249
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 249
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 248
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 246
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 245
Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: Results from the ITACa randomized clinical trial 242
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation 242
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 241
Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial 239
Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities 239
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study 238
No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC) 238
Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study 236
Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study 235
Right- vs. left-sided metastatic colorectal cancer: Differences in tumor biology and bevacizumab efficacy 234
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 233
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 232
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 230
Radiofrequency Ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival 224
KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC) 224
The Italian Rare Pancreatic Exocrine Cancer Initiative 224
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 222
Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report 219
Increase of reports of suspected adverse drug reactions in oncology 218
Sarcopenia in gastric cancer: when the loss costs too much 217
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 216
Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials 216
Chemoradiotherapy (Gemox plus helical tomotherapy) for unresectable locally advanced pancreatic cancer: A phase II study 214
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 213
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease 209
Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials 208
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: Case report 207
Erratum to “Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life” [Eur J Cancer (2016) 69 (110–118)] (S095980491632487X)(10.1016/j.ejca.2016.10.004) 204
BRAF-mutated colorectal cancer: Clinical and molecular insights 204
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 203
Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer 203
Clustered protocadherins methylation alterations in cancer 202
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: Results from a retrospective analysis of the HCC-AVR group 202
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study 200
Improved stool DNA integrity method for early colorectal cancer diagnosis 200
Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals 200
Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes 199
Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab 196
Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib 196
Shifts of Faecal Microbiota during Sporadic Colorectal Carcinogenesis 194
Treatment of squamous cell carcinoma of the anal canal (SCCA): A new era? 193
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 185
Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; Potential marker of disease recurrence 182
EGFR, HER-2 and KRAS in canine gastric epithelial tumors: A potential human model? 180
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 179
Prevalence of and risk factors for fatty liver in the general population of Northern Italy: The Bagnacavallo Study 178
Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics 177
Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: Results from the ITACa trial 176
NEMESI: A retrospective observational longitudinal study to investigate italian early breast cancer (EBC) patient characteristics and treatment 176
Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019 175
IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab 174
Hemangioblastoma of the gastrointestinal tract: A first case 170
NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus 169
Incorporating alpha-fetoprotein within dimensional criteria for hepatocellular carcinoma transplantation 163
Oxidative Molecular Mechanisms Underlying Liver Diseases: From Systems Biology to the Personalized Medicine 162
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 160
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 157
Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy 154
Retrospective Analysis on the Management of Metastatic Gastric Cancer Patients. A Mono-institutional Experience. What happens in Clinical Practice? 149
Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma 148
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 147
Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort 143
BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives 139
Totale 23.244
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.639
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.639
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021752 0 0 0 0 0 0 0 0 0 0 383 369
2021/20222.268 318 153 159 113 68 185 81 122 224 259 376 210
2022/20232.022 227 196 130 174 279 237 65 215 288 21 94 96
2023/2024900 41 77 50 120 141 32 68 126 22 25 29 169
2024/20254.052 133 39 33 256 957 686 433 227 449 167 212 460
2025/20265.789 383 232 384 533 913 393 913 412 740 801 85 0
Totale 24.349